Clinical Trials

Inclusion Criteria:

- Males age ≥ 18 years who are receiving post-operative radiation therapy to the prostate fossa, with or without inclusion of the pelvic lymph nodes, for biochemical
recurrences after radical prostatectomy.

- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≤ 2.

- Ability to complete questionnaire(s) by themselves or with assistance.

- Provide written informed consent.

- Willingness and ability to complete protocol-specified follow-up (during the active monitoring phase of the study).

Exclusion Criteria:

- Current evidence of untreated metastatic prostate cancer involving nonregional lymph nodes outside of the bony pelvis, bone, or visceral organs.

- Receipt of cytotoxic chemotherapy within 3 months prior to enrollment.

- Prior radiation therapy to pelvis such that the proposed study treatment volume received 10 Gy or greater.

- Co-morbid severe concurrent disease that would result in a life expectancy of < 5 years.

- Diabetes mellitus-associated vascular ulcers or wounding healing problems, inflammatory bowel disease, or a diagnosed connective tissue disorder.

- Medical or psychiatric conditions that preclude informed decision-making or adherence to study protocols.

- Men of childbearing potential who are unwilling to employ adequate contraception.

Eligibility last updated 4/27/23. Questions regarding updates should be directed to the study team contact.